 WATERTOWN, Mass., Sept. 12, 2022 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Companys Management will participate in upcoming investor conferences in September. 